Scientists test new imaging agent to spy on pancreatic tumors
NCT ID NCT07114939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive tracer called [18F]FTT to see how well it lights up pancreatic neuroendocrine tumors on a PET scan. Twelve adults with advanced tumors will receive one injection and have a whole-body scan. The goal is to measure tumor activity and compare it with lab tests, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania, Perelman Center for Advanced Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Promising drug trial for rare pancreatic cancer stopped early
- Zapping pancreatic tumors without surgery: a safer approach?
- New PET scan agent aims to better detect rare tumors
- Custom mRNA vaccine takes on rare endocrine cancers